Equities Analysts Offer Predictions for VNDA FY2025 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Cantor Fitzgerald dropped their FY2025 earnings estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings of ($1.55) per share for the year, down from their prior estimate of ($1.26). The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share.

A number of other analysts have also recently weighed in on VNDA. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $3.98 on Monday. The company’s 50 day simple moving average is $4.50 and its 200 day simple moving average is $4.65. The stock has a market capitalization of $234.56 million, a price-to-earnings ratio of -12.44 and a beta of 0.69. Vanda Pharmaceuticals has a 1 year low of $3.85 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The company had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantinno Capital Management LP acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at $48,000. Linden Thomas Advisory Services LLC acquired a new position in Vanda Pharmaceuticals in the first quarter valued at $49,000. XTX Topco Ltd acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at $69,000. Nations Financial Group Inc. IA ADV acquired a new position in Vanda Pharmaceuticals in the first quarter valued at $67,000. Finally, Zacks Investment Management acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at $74,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Insider Buying and Selling

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. This represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have acquired a total of 32,000 shares of company stock valued at $151,180 over the last 90 days. 10.00% of the stock is owned by insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.